WELCOME: Introduce yourself & read the community guidelines

traveltech_sara said:

The gap between trial results and real-world results is consistent and it is not fraud.

This answered a question I did not know how to ask.

Clinical perspective, offered as context rather than as advice.

Admin said:

...regarding the trial evidence...

I think this is an underappreciated point. To expand on it with some data:

A recent meta-analysis of 22 RCTs (n=18,900) found that the trial evidence was associated with a consistent effect size across diverse patient populations[1].

The NNT was 20, which is comparable to antihypertensives for stroke reduction. That's a strong clinical argument for this approach.

Dr.MetabolicMD said:

Relative and absolute effects need reading together.

Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to:

1. Point estimate (HR/RR/OR) — center of the diamond
2. Confidence interval width — precision of the estimate
3. I² statistic — heterogeneity across studies
4. Individual study weights — are results driven by one large trial?
5. Prediction interval — range of plausible true effects in future settings

The the trial evidence meta-analysis shows a pooled RR of 0.80 (95% CI 0.67-0.90), I²=38%. This is a robust and consistent effect.

Admin said:

WELCOME: Introduce yourself & read the community guidelines Public Square is a small room with a long memory.

Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational studies can provide useful evidence.

A recent PSM study of 12,000 GLP-1 users vs matched controls showed reduced MI incidence (HR 0.78) over 3 years of follow-up[1].

These results complement the RCT data and suggest the benefits translate to real-world populations.

Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source. Carry on.